Pfizer (PFE) Raises Quarterly Dividend 2.6% to $0.40; 3% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Pfizer’s (PFE) $6.7B Arena Acquisition is Priced Reasonably, May Offer Additional Upside, Pfizer Making Good Use of Cash – Analyst
December 13, 2021 9:30 AM ESTEarlier today, Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately... More
Low Valuations to Drive Pharma M&A in 2022 - Analyst
December 13, 2021 8:50 AM ESTIn light of recently announced major biotech acquisitions - Dicerna (NASDAQ: DRNA) was acquired by Novo Nordisk (NYSE: NVO) for $38 (~80% premium) and Arena (NASDAQ: ARNA) now being acquired for $100/sh (~100% premium) by Pfizer... More
Boosters give 70-75% Omicron protection, U.K. study shows - Bloomberg
December 10, 2021 11:46 AM ESTBoosters give 70-75% Omicron protection, U.K. study shows - Bloomberg
... MorePfizer's (PFE) Cibinqo Approved in EU for Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
December 10, 2021 9:27 AM ESTPfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved the 100 mg and 200 mg doses of Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. Additionally, a 50 mg dose was approved to treat moderate-to-severe AD specifically in... More
Arvinas Inc. (ARVN) and Pfizer (PFE) Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breas
December 10, 2021 8:12 AM ESTArvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced an update on Phase 1 dose escalation data of ARV-471, a novel PROTAC® estrogen receptor (ER) degrader, which is being co-developed for the treatment of patients with locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-). These data were presented as a virtual spotlight poster session at the 2021 San Antonio Breast Cancer Symposium (SABCS) and showed:
ARV-471 demonstrated antitumor activity in CDK4/6 inhibitor-pretreated patients with a clinical benefit rate... MorePfizer (PFE) PT Raised to $54 at Barclays
December 10, 2021 4:36 AM ESTBarclays analyst Carter Gould raised the price target on Pfizer (NYSE: PFE) to $54.00 (from $44.00) while maintaining a Equalweight rating.... More
CDC Expands Booster Recommendations To 16-and-17-year-olds - Bloomberg
December 9, 2021 2:30 PM ESTCDC Expands Booster Recommendations To 16-and-17-year-olds - Bloomberg
... More